View ValuationBIOTON 将来の成長Future 基準チェック /06現在、 BIOTONの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Mar 05Full year 2025 earnings released: EPS: zł0.04 (vs zł0.18 loss in FY 2024)Full year 2025 results: EPS: zł0.04 (up from zł0.18 loss in FY 2024). Revenue: zł282.5m (up 36% from FY 2024). Net income: zł3.39m (up zł19.1m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.お知らせ • Jan 29+ 4 more updatesBIOTON S.A. to Report Q4, 2025 Results on Feb 27, 2026BIOTON S.A. announced that they will report Q4, 2025 results on Feb 27, 2026Reported Earnings • Nov 02Third quarter 2025 earnings released: EPS: zł0.049 (vs zł0.039 loss in 3Q 2024)Third quarter 2025 results: EPS: zł0.049 (up from zł0.039 loss in 3Q 2024). Revenue: zł72.7m (up 73% from 3Q 2024). Net income: zł4.20m (up zł7.57m from 3Q 2024). Profit margin: 5.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł79.9m (up 58% from 2Q 2024). Net income: zł3.24m (up zł6.03m from 2Q 2024). Profit margin: 4.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.New Risk • Sep 18New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • May 20BIOTON S.A., Annual General Meeting, Jun 23, 2025BIOTON S.A., Annual General Meeting, Jun 23, 2025.お知らせ • Apr 22+ 2 more updatesBIOTON S.A. to Report First Half, 2025 Results on Aug 28, 2025BIOTON S.A. announced that they will report first half, 2025 results on Aug 28, 2025Reported Earnings • Feb 07Full year 2024 earnings released: zł0.18 loss per share (vs zł0.026 profit in FY 2023)Full year 2024 results: zł0.18 loss per share (down from zł0.026 profit in FY 2023). Revenue: zł207.8m (up 14% from FY 2023). Net loss: zł15.7m (down zł17.9m from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 10Third quarter 2024 earnings released: zł0.039 loss per share (vs zł0.051 loss in 3Q 2023)Third quarter 2024 results: zł0.039 loss per share (improved from zł0.051 loss in 3Q 2023). Revenue: zł42.0m (down 17% from 3Q 2023). Net loss: zł3.37m (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł50.6m (up 3.2% from 2Q 2023). Net loss: zł2.79m (down 296% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.Reported Earnings • May 19First quarter 2024 earnings released: zł0.059 loss per share (vs zł0.002 loss in 1Q 2023)First quarter 2024 results: zł0.059 loss per share (further deteriorated from zł0.002 loss in 1Q 2023). Revenue: zł37.5m (up 9.0% from 1Q 2023). Net loss: zł5.04m (loss widened zł4.91m from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.お知らせ • May 10BIOTON S.A., Annual General Meeting, Jun 06, 2024BIOTON S.A., Annual General Meeting, Jun 06, 2024.Reported Earnings • Mar 31Full year 2023 earnings releasedFull year 2023 results: Revenue: zł181.6m (down 22% from FY 2022). Net income: zł2.28m (up 60% from FY 2022). Profit margin: 1.3% (up from 0.6% in FY 2022). The increase in margin was driven by lower expenses.お知らせ • Feb 02+ 3 more updatesBIOTON S.A. to Report First Half, 2024 Results on Aug 27, 2024BIOTON S.A. announced that they will report first half, 2024 results on Aug 27, 2024New Risk • Nov 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (zł322.8m market cap, or US$77.1m).Reported Earnings • Nov 02Third quarter 2023 earnings released: zł0.051 loss per share (vs zł0.023 loss in 3Q 2022)Third quarter 2023 results: zł0.051 loss per share (further deteriorated from zł0.023 loss in 3Q 2022). Revenue: zł50.7m (down 12% from 3Q 2022). Net loss: zł4.42m (loss widened 128% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: zł0.017 (vs zł0.017 in 2Q 2022)Second quarter 2023 results: EPS: zł0.017 (in line with 2Q 2022). Revenue: zł49.0m (up 2.1% from 2Q 2022). Net income: zł1.42m (down 2.8% from 2Q 2022). Profit margin: 2.9% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 31First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • May 26BIOTON S.A., Annual General Meeting, Jun 21, 2023BIOTON S.A., Annual General Meeting, Jun 21, 2023, at 10:00 Central European Standard Time.Reported Earnings • May 04First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Feb 03+ 3 more updatesBIOTON S.A. to Report First Half, 2023 Results on Aug 31, 2023BIOTON S.A. announced that they will report first half, 2023 results on Aug 31, 2023Reported Earnings • Nov 06Third quarter 2022 earnings released: zł0.023 loss per share (vs zł0.054 profit in 3Q 2021)Third quarter 2022 results: zł0.023 loss per share (down from zł0.054 profit in 3Q 2021). Revenue: zł57.5m (up 20% from 3Q 2021). Net loss: zł1.93m (down 142% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 02Second quarter 2022 earnings released: EPS: zł0.017 (vs zł0.043 in 2Q 2021)Second quarter 2022 results: EPS: zł0.017 (down from zł0.043 in 2Q 2021). Revenue: zł48.1m (up 32% from 2Q 2021). Net income: zł1.46m (down 60% from 2Q 2021). Profit margin: 3.0% (down from 10.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Jun 01BIOTON S.A., Annual General Meeting, Jun 30, 2022BIOTON S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central European Standard Time.分析記事 • Mar 21We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 45% share price gain to zł5.50, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 32x in the Biotechs industry in Poland. Total returns to shareholders of 11% over the past three years.Reported Earnings • Nov 03Third quarter 2021 earnings released: EPS zł0.054 (vs zł0.028 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł47.8m (up 10% from 3Q 2020). Net income: zł4.61m (up 93% from 3Q 2020). Profit margin: 9.6% (up from 5.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Sep 08The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The BusinessEven though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS zł0.043 (vs zł0.08 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł36.5m (down 27% from 2Q 2020). Net income: zł3.67m (down 46% from 2Q 2020). Profit margin: 10.0% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 8% per year.Reported Earnings • Apr 19Full year 2020 earnings released: EPS zł0.40 (vs zł1.48 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł221.8m (up 9.8% from FY 2019). Net income: zł33.9m (up zł160.6m from FY 2019). Profit margin: 15% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 22New 90-day high: zł4.64The company is up 1.0% from its price of zł4.57 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 13% over the same period.お知らせ • Jan 30+ 2 more updatesBIOTON S.A. to Report Q3, 2021 Results on Oct 29, 2021BIOTON S.A. announced that they will report Q3, 2021 results on Oct 29, 2021Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS zł0.028The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: zł43.4m (down 3.3% from 3Q 2019). Net income: zł2.39m (up zł9.73m from 3Q 2019). Profit margin: 5.5% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Is New 90 Day High Low • Sep 24New 90-day low: zł4.16The company is down 11% from its price of zł4.65 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、BIOTON は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:BIO - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202528331023N/A9/30/2025296-32432N/A6/30/2025265-102332N/A3/31/2025236-162333N/A12/31/2024208-162536N/A9/30/2024178-61338N/A6/30/2024186-72154N/A3/31/2024185-3651N/A12/31/20231822-540N/A9/30/20232122-431N/A6/30/20232184337N/A3/31/202321741850N/A12/31/202223312756N/A9/30/2022197-44061N/A6/30/202218831939N/A3/31/20221765-28N/A12/31/20211633-76N/A9/30/202121222-8-1N/A6/30/202120820-5-5N/A3/31/2021222232831N/A12/31/2020222343742N/A9/30/2020185-242445N/A6/30/2020186-344177N/A3/31/2020208-1481259N/A12/31/2019202-127-747N/A9/30/2019209-98N/A64N/A6/30/2019213-109N/A9N/A3/31/201922676N/A11N/A12/31/201824126N/A28N/A9/30/201829429N/A1N/A6/30/201833747N/A35N/A3/31/2018338-39N/A23N/A12/31/2017362-27N/A2N/A9/30/2017303-31N/A3N/A6/30/2017286-31N/A-14N/A3/31/2017279-28N/A9N/A12/31/2016278-16N/A23N/A9/30/2016251-536N/A33N/A6/30/2016289-526N/A39N/A3/31/2016308-522N/A15N/A12/31/2015333-522N/A24N/A9/30/201541714N/A36N/A6/30/201541110N/A43N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:53終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BIOTON S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Vladimira UrbankovaErste Group Bank AGOvidiu FerWood & Company
Reported Earnings • Mar 05Full year 2025 earnings released: EPS: zł0.04 (vs zł0.18 loss in FY 2024)Full year 2025 results: EPS: zł0.04 (up from zł0.18 loss in FY 2024). Revenue: zł282.5m (up 36% from FY 2024). Net income: zł3.39m (up zł19.1m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 29+ 4 more updatesBIOTON S.A. to Report Q4, 2025 Results on Feb 27, 2026BIOTON S.A. announced that they will report Q4, 2025 results on Feb 27, 2026
Reported Earnings • Nov 02Third quarter 2025 earnings released: EPS: zł0.049 (vs zł0.039 loss in 3Q 2024)Third quarter 2025 results: EPS: zł0.049 (up from zł0.039 loss in 3Q 2024). Revenue: zł72.7m (up 73% from 3Q 2024). Net income: zł4.20m (up zł7.57m from 3Q 2024). Profit margin: 5.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł79.9m (up 58% from 2Q 2024). Net income: zł3.24m (up zł6.03m from 2Q 2024). Profit margin: 4.1% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
New Risk • Sep 18New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • May 20BIOTON S.A., Annual General Meeting, Jun 23, 2025BIOTON S.A., Annual General Meeting, Jun 23, 2025.
お知らせ • Apr 22+ 2 more updatesBIOTON S.A. to Report First Half, 2025 Results on Aug 28, 2025BIOTON S.A. announced that they will report first half, 2025 results on Aug 28, 2025
Reported Earnings • Feb 07Full year 2024 earnings released: zł0.18 loss per share (vs zł0.026 profit in FY 2023)Full year 2024 results: zł0.18 loss per share (down from zł0.026 profit in FY 2023). Revenue: zł207.8m (up 14% from FY 2023). Net loss: zł15.7m (down zł17.9m from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 10Third quarter 2024 earnings released: zł0.039 loss per share (vs zł0.051 loss in 3Q 2023)Third quarter 2024 results: zł0.039 loss per share (improved from zł0.051 loss in 3Q 2023). Revenue: zł42.0m (down 17% from 3Q 2023). Net loss: zł3.37m (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł50.6m (up 3.2% from 2Q 2023). Net loss: zł2.79m (down 296% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 19First quarter 2024 earnings released: zł0.059 loss per share (vs zł0.002 loss in 1Q 2023)First quarter 2024 results: zł0.059 loss per share (further deteriorated from zł0.002 loss in 1Q 2023). Revenue: zł37.5m (up 9.0% from 1Q 2023). Net loss: zł5.04m (loss widened zł4.91m from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
お知らせ • May 10BIOTON S.A., Annual General Meeting, Jun 06, 2024BIOTON S.A., Annual General Meeting, Jun 06, 2024.
Reported Earnings • Mar 31Full year 2023 earnings releasedFull year 2023 results: Revenue: zł181.6m (down 22% from FY 2022). Net income: zł2.28m (up 60% from FY 2022). Profit margin: 1.3% (up from 0.6% in FY 2022). The increase in margin was driven by lower expenses.
お知らせ • Feb 02+ 3 more updatesBIOTON S.A. to Report First Half, 2024 Results on Aug 27, 2024BIOTON S.A. announced that they will report first half, 2024 results on Aug 27, 2024
New Risk • Nov 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (zł322.8m market cap, or US$77.1m).
Reported Earnings • Nov 02Third quarter 2023 earnings released: zł0.051 loss per share (vs zł0.023 loss in 3Q 2022)Third quarter 2023 results: zł0.051 loss per share (further deteriorated from zł0.023 loss in 3Q 2022). Revenue: zł50.7m (down 12% from 3Q 2022). Net loss: zł4.42m (loss widened 128% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: zł0.017 (vs zł0.017 in 2Q 2022)Second quarter 2023 results: EPS: zł0.017 (in line with 2Q 2022). Revenue: zł49.0m (up 2.1% from 2Q 2022). Net income: zł1.42m (down 2.8% from 2Q 2022). Profit margin: 2.9% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 31First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • May 26BIOTON S.A., Annual General Meeting, Jun 21, 2023BIOTON S.A., Annual General Meeting, Jun 21, 2023, at 10:00 Central European Standard Time.
Reported Earnings • May 04First quarter 2023 earnings released: zł0.002 loss per share (vs zł0.036 loss in 1Q 2022)First quarter 2023 results: zł0.002 loss per share (improved from zł0.036 loss in 1Q 2022). Revenue: zł34.4m (down 31% from 1Q 2022). Net loss: zł134.0k (loss narrowed 96% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Feb 03+ 3 more updatesBIOTON S.A. to Report First Half, 2023 Results on Aug 31, 2023BIOTON S.A. announced that they will report first half, 2023 results on Aug 31, 2023
Reported Earnings • Nov 06Third quarter 2022 earnings released: zł0.023 loss per share (vs zł0.054 profit in 3Q 2021)Third quarter 2022 results: zł0.023 loss per share (down from zł0.054 profit in 3Q 2021). Revenue: zł57.5m (up 20% from 3Q 2021). Net loss: zł1.93m (down 142% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 02Second quarter 2022 earnings released: EPS: zł0.017 (vs zł0.043 in 2Q 2021)Second quarter 2022 results: EPS: zł0.017 (down from zł0.043 in 2Q 2021). Revenue: zł48.1m (up 32% from 2Q 2021). Net income: zł1.46m (down 60% from 2Q 2021). Profit margin: 3.0% (down from 10.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Jun 01BIOTON S.A., Annual General Meeting, Jun 30, 2022BIOTON S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central European Standard Time.
分析記事 • Mar 21We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 45% share price gain to zł5.50, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 32x in the Biotechs industry in Poland. Total returns to shareholders of 11% over the past three years.
Reported Earnings • Nov 03Third quarter 2021 earnings released: EPS zł0.054 (vs zł0.028 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł47.8m (up 10% from 3Q 2020). Net income: zł4.61m (up 93% from 3Q 2020). Profit margin: 9.6% (up from 5.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Sep 08The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The BusinessEven though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...
Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS zł0.043 (vs zł0.08 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł36.5m (down 27% from 2Q 2020). Net income: zł3.67m (down 46% from 2Q 2020). Profit margin: 10.0% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 8% per year.
Reported Earnings • Apr 19Full year 2020 earnings released: EPS zł0.40 (vs zł1.48 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł221.8m (up 9.8% from FY 2019). Net income: zł33.9m (up zł160.6m from FY 2019). Profit margin: 15% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 22New 90-day high: zł4.64The company is up 1.0% from its price of zł4.57 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 13% over the same period.
お知らせ • Jan 30+ 2 more updatesBIOTON S.A. to Report Q3, 2021 Results on Oct 29, 2021BIOTON S.A. announced that they will report Q3, 2021 results on Oct 29, 2021
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS zł0.028The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: zł43.4m (down 3.3% from 3Q 2019). Net income: zł2.39m (up zł9.73m from 3Q 2019). Profit margin: 5.5% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Is New 90 Day High Low • Sep 24New 90-day low: zł4.16The company is down 11% from its price of zł4.65 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period.